On Apr. 22, 2020, the FDA granted accelerated approval to Trodelvy (sacituzumab govitecan-hziy), developed by Immunomedics, for the treatment of adult patients with triple-negative breast cancer that has spread to other parts of the body. Patients must have received at least two prior therapies before taking Trodelvy.